Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
- Autores
- Denninghoff, Valeria Cecilia; von Petery, Felicitas; Fresno, Cristóbal; Galarza, Mercedes; Torres, Florencia; Avagnina, Alejandra; Fishkel, Vanina; Krupitzki, Hugo Bernardo; Fiorillo, Angel Eduardo; Monge, Fernando Carlos
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7, 548 new cervical cancer cases are diagnosed each year with 3, 932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2, 273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1, 000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare.
Fil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: von Petery, Felicitas. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Fresno, Cristóbal. Universidad Anahuac Mexico; México
Fil: Galarza, Mercedes. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Torres, Florencia. No especifíca;
Fil: Avagnina, Alejandra. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Fishkel, Vanina. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Krupitzki, Hugo Bernardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: Fiorillo, Angel Eduardo. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Monge, Fernando Carlos. Centro de Educación Medica E Invest.clinicas; Argentina - Materia
-
CERVICAL CANCER
UNIVERSITY HOSPITAL - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/210314
Ver los metadatos del registro completo
id |
CONICETDig_930977f3c91f343e97ea8ec8e852b5df |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/210314 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospitalDenninghoff, Valeria Ceciliavon Petery, FelicitasFresno, CristóbalGalarza, MercedesTorres, FlorenciaAvagnina, AlejandraFishkel, VaninaKrupitzki, Hugo BernardoFiorillo, Angel EduardoMonge, Fernando CarlosCERVICAL CANCERUNIVERSITY HOSPITALhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7, 548 new cervical cancer cases are diagnosed each year with 3, 932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2, 273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1, 000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare.Fil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: von Petery, Felicitas. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Fresno, Cristóbal. Universidad Anahuac Mexico; MéxicoFil: Galarza, Mercedes. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Torres, Florencia. No especifíca;Fil: Avagnina, Alejandra. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Fishkel, Vanina. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Krupitzki, Hugo Bernardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: Fiorillo, Angel Eduardo. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Monge, Fernando Carlos. Centro de Educación Medica E Invest.clinicas; ArgentinaPublic Library of Science2022-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/210314Denninghoff, Valeria Cecilia; von Petery, Felicitas; Fresno, Cristóbal; Galarza, Mercedes; Torres, Florencia; et al.; Clinical implementation of a cervical cancer screening program via co-testing at a university hospital; Public Library of Science; Plos One; 17; 12-2022; 1-141932-6203CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278476info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0278476info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:51:39Zoai:ri.conicet.gov.ar:11336/210314instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:51:39.604CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital |
title |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital |
spellingShingle |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital Denninghoff, Valeria Cecilia CERVICAL CANCER UNIVERSITY HOSPITAL |
title_short |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital |
title_full |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital |
title_fullStr |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital |
title_full_unstemmed |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital |
title_sort |
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital |
dc.creator.none.fl_str_mv |
Denninghoff, Valeria Cecilia von Petery, Felicitas Fresno, Cristóbal Galarza, Mercedes Torres, Florencia Avagnina, Alejandra Fishkel, Vanina Krupitzki, Hugo Bernardo Fiorillo, Angel Eduardo Monge, Fernando Carlos |
author |
Denninghoff, Valeria Cecilia |
author_facet |
Denninghoff, Valeria Cecilia von Petery, Felicitas Fresno, Cristóbal Galarza, Mercedes Torres, Florencia Avagnina, Alejandra Fishkel, Vanina Krupitzki, Hugo Bernardo Fiorillo, Angel Eduardo Monge, Fernando Carlos |
author_role |
author |
author2 |
von Petery, Felicitas Fresno, Cristóbal Galarza, Mercedes Torres, Florencia Avagnina, Alejandra Fishkel, Vanina Krupitzki, Hugo Bernardo Fiorillo, Angel Eduardo Monge, Fernando Carlos |
author2_role |
author author author author author author author author author |
dc.subject.none.fl_str_mv |
CERVICAL CANCER UNIVERSITY HOSPITAL |
topic |
CERVICAL CANCER UNIVERSITY HOSPITAL |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7, 548 new cervical cancer cases are diagnosed each year with 3, 932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2, 273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1, 000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare. Fil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina Fil: von Petery, Felicitas. Centro de Educación Medica E Invest.clinicas; Argentina Fil: Fresno, Cristóbal. Universidad Anahuac Mexico; México Fil: Galarza, Mercedes. Centro de Educación Medica E Invest.clinicas; Argentina Fil: Torres, Florencia. No especifíca; Fil: Avagnina, Alejandra. Centro de Educación Medica E Invest.clinicas; Argentina Fil: Fishkel, Vanina. Centro de Educación Medica E Invest.clinicas; Argentina Fil: Krupitzki, Hugo Bernardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina Fil: Fiorillo, Angel Eduardo. Centro de Educación Medica E Invest.clinicas; Argentina Fil: Monge, Fernando Carlos. Centro de Educación Medica E Invest.clinicas; Argentina |
description |
The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7, 548 new cervical cancer cases are diagnosed each year with 3, 932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2, 273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1, 000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/210314 Denninghoff, Valeria Cecilia; von Petery, Felicitas; Fresno, Cristóbal; Galarza, Mercedes; Torres, Florencia; et al.; Clinical implementation of a cervical cancer screening program via co-testing at a university hospital; Public Library of Science; Plos One; 17; 12-2022; 1-14 1932-6203 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/210314 |
identifier_str_mv |
Denninghoff, Valeria Cecilia; von Petery, Felicitas; Fresno, Cristóbal; Galarza, Mercedes; Torres, Florencia; et al.; Clinical implementation of a cervical cancer screening program via co-testing at a university hospital; Public Library of Science; Plos One; 17; 12-2022; 1-14 1932-6203 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278476 info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0278476 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Public Library of Science |
publisher.none.fl_str_mv |
Public Library of Science |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1846083043336388608 |
score |
13.22299 |